London, 21st December 2020
Celix Pharma raises GBP 2.5mn in seed funding round
Celix Pharma, a London-based startup in the UK / EU generic pharmaceutical space, announced
that it has raised GBP 2.5million in seed funding.
The round was led by MediOptions, a strategic investor in the UK pharmaceutical market. Other investors include Vishar S Vasudevan (Vasu), who was the Global CFO of Dr. Reddy’s Laboratories Ltd. for over 22 years and joins the Board of Celix Pharma.
Celix was founded in 2020 by chief executive officer, Subir Kohli and chief operating officer, Shantreddy Soogareddy. The founders have decades of experience in the UK and EU generic pharmaceutical industry, in roles spanning the entire value-chain, from product development to commercial sales & marketing.
Celix Pharma focuses on bridging gaps in the market by identifying new off-patent products and opportunities arising from supply disruptions or pricing inconsistencies for payers like the NHS.
The company aims to launch high quality, affordable medicines with a sustainable supply chain to address these gaps. Celix Pharma operates across both sectors of the market - primary and secondary care and will provide its customers with a range of generics, branded generics, and hospital specialty products.
The fresh funding will be used to create a portfolio of products that Celix is bringing to market through collaborative product development and in-licensing.
Commenting on the seed funding, Subir Kohli, Co-founder and CEO said: "This seed round gives us
a great platform to establish Celix over the next few years as we develop and launch an exciting portfolio of products across channels, therapeutic categories and dosage forms. Additionally, the investors bring in a wealth of knowledge and expertise, which will hold Celix in good stead as we embark on this journey together."
Vasu added, "I am excited to be a part of the Celix Pharma journey, both as an investor and a
member of the Board. With the energy and passion of the founders, their ideas, and a clear focus on execution, I am convinced that Celix will soon become a meaningful player in the UK and European generic market”.
About Celix Pharma Ltd
Celix Pharma is a London-based generic pharmaceutical company founded in 2020 with an overarching goal to bring high quality, affordable, generic medicines with a sustainable supply chain to the UK. Celix Pharma focuses on bridging gaps in the market by identifying product opportunities arising from complexities in development and/or manufacturing, addressing supply disruptions and future patent expiries. Celix Pharma is building a portfolio across both, primary-care and secondary-care, with a range of generics, branded generics, and hospital specialty products. Celix Pharma’s business model is built around creating a commercially-led, customer-focused organization supported with strategic partnerships in R&D and manufacturing.
For more information, visit www.celixpharma.com